New evidence suggests that adding the targeted therapy ibrutinib (Imbruvica) to a standard chemotherapy regimen can improve how long some younger people with a specific form of diffuse large B-cell lymphoma (DLBCL) live.
from Top Health News -- ScienceDaily https://ift.tt/3k61uJ2
No comments:
Post a Comment